Indofarma Tbk PT


Indofarma Tbk PT

Health CarePharmaceuticals and Biotechnology
  • Price (IDR)835.00
  • Today's Change-15.00 / -1.76%
  • Shares traded146.50k
  • 1 Year change-60.05%
  • Beta-0.8267
Data delayed at least 10 minutes, as of Feb 08 2023 08:12 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Events & Activity

  • INAF:JKT price moved over +1.20% to 845.00
  • INAF:JKT price falls below 15-day moving average to 835.00 at 14:17 GMT
  • INAF:JKT price rises above 15-day moving average to 845.00 at 13:51 GMT
  • INAF:JKT price rises above 15-day moving average to 840.00 at 14:08 GMT

Key statistics

On Wednesday, Indofarma Tbk PT (INAF:JKT) closed at 835.00, 3.73% above its 52-week low of 805.00, set on Jan 09, 2023.
52-week range
805.00Jan 09 20232,120.00Feb 09 2022
Previous close850.00
Average volume149.33k
Shares outstanding3.10bn
Free float599.27m
P/E (TTM)--
Market cap2.63tn IDR
EPS (TTM)-72.15
Data delayed at least 10 minutes, as of Feb 08 2023 08:12 GMT.
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.